吴茱萸碱对人肝癌细胞HepG2的生长抑制及诱导凋亡作用  

Proliferation-inhibited and apoptosis-inducted effects of evodiamine on human hepatoma cell line HepG2

作　　者：朱丽红[1] 刘小东[2] 谭宇蕙[2] 李杰芬[1] 杜标炎[3] 吴映雅[2] 

机构地区：[1]广州中医药大学中医基础实验室,广东广州510405 [2]广州中医药大学生化教研室,广东广州510405 [3]广州中医药大学病理学教研室,广东广州510405

出　　处：《中国药理学通报》2009年第1期68-71,共4页Chinese Pharmacological Bulletin

基　　金：国家自然科学基金面上资助项目(No30672747);广州中医药大学创新基金资助项目

摘　　要：目的探讨吴茱萸碱对人肝癌细胞HepG2的生长抑制、诱导凋亡和对细胞周期的影响。方法体外试验MIT法测存活率,DAPI染色观察细胞凋亡形态,流式细胞术、彗星电泳技术分析药物对DNA作用。结果吴茱萸碱能抑制人肝癌细胞HepG2的生长。用64、16、4、1、0.25μmol.L-1浓度的吴茱萸碱处理HepG2细胞72 h的抑制率分别为74.0%、69.0%、60.5%、44.0%、16.4%。DAPI染色后吴茱萸碱组癌细胞均表现出较为典型的细胞凋亡特征。流式细胞仪检测1μmol.L-1吴茱萸碱作用24和36 h出现亚二倍体凋亡峰,细胞周期阻滞于G2/M期。凋亡率对照组为4%,1μmol.L-1吴茱萸碱作用12、24、36 h的凋亡率分别为4.4%、18.0%、30.3%。彗星电泳显示1μmol.L-1吴茱萸碱作用24和48 h后,细胞后面形成长的拖尾,平均光密度值较阴性对照组降低,彗星尾距较阴性对照组增加,且二者的改变与作用时间相关。结论吴茱萸碱能抑制人肝癌细胞HepG2的生长及诱导其凋亡。Aim To explore the proliferation-inhibited, apoptosis - induced and cell cycle - regulated effect of evodiamine on human hepatoma Methods MTT, Dapi assay, flow comet assay were used. Results cell line HepG2. cytometry analysis, Evodiamine could significantly inhibit the growth of human hepatoma cell line HepG2. After 72 hours of treatment with evodiamine at different concentrations （64, 16,4, 1,0.25 μmol·L-1）, the inhibitory rate of HepG2 was 74.0% ,69.0% ,60. 5% ,44.0% and 16.4% , respeetively. Meanwhile, HepG2 showed typical apoptosis. After 24 and 36 hours＇ treatment with evodiamine （1μmol·L-1）,a typical subdiploid peak before G0/G1 phase was observed by flow cytometry and cell cycle was arrested in the G2/M phase, while the rate of apop- tosis was 4. 4% ,18.0% and 30.3% of treatment with evodiamine for 12,24 and 36 hours respectively. After 24 and 36 hours＇ treatment with evodiamine （ 1 μmol·L-1 ）, the average optical density was lower than that of the control and the length of tail increased compared with the control. Meanwhile the changes were related with time. Conclusion Evodiamine inhibits the proliferation and induces apoptosis of HepG2.

关 键 词：吴茱萸碱 细胞凋亡 肝癌 

分 类 号：R284.1[医药卫生—中药学] R329.25[医药卫生—中医学]